Percentages of Swedish N. gonorrhoeae (GC) strains comprising b-lactamase production, decreased susceptibility or resistance in 1998 and 2000-2005.

 

 

1998
(n=348)

2000
(n=131)

2001
(n=141)

2002
(n=120)

2003
(n=130)

2004

(n=149)

2005

(n=497)#

b-lactamase production

 

 

24

 

37

 

37

 

39


22


26


23

Ampicillin MIC*, **

 

 

 

 

 

 

 

>0,125 - £2,0

52

40

46

48

70

63

76

>2,0

 

 0

 0

 0

 0

 0

0

0

Cefixime
MIC*

 

 

 

 

 

 

 

>0,064 - £0,5

 -

 -

 -

 4

 0

1

0

>0,5

 

 -

 -

 -

 0

 0

0

0

Ceftriaxone MIC*

 

 

 

 

 

 

 

>0,064 - £0,5

 0

 -

 -

 3

 0

1

1

>0,5

 

 0

 -

 -

 0

 0

0

0

Azithromycin MIC*

 

 

 

 

 

 

 

>0,5 - £1,0

 1

 -

 -

 2

 0

0

1

>1,0

 

 0

 -

 -

 0

 1

0

0

Ciprofloxacin MIC*

 

 

 

 

 

 

 

>0,064***

 18

47

52

58

 56

51

49

 

 

 

 

 

 

 

 

Spectinomycin MIC*

 

 

 

 

 

 

 

>32

 0

 0

 0

 0

 0

0

0

#      For 2005, all strains submitted to the National Reference Laboratory for Pathogenic Neisseria, Örebro,
        Sweden and to the Karolinska University Hospital Huddinge, Stockholm, Sweden are presented.

*        Minimum inhibitory concentration (MIC) in mg/L.

**   PPNG strains are not included; 1998 (n=266), 2000 (n=83), 2001 (n=89), 2002 (n=73), 2003 (n=102),
       2004 (n=110), and 2005 (n=384).

   ***  For ciprofloxacin, different SIR breakpoints are used at the two laboratories. Consequently, strains with
          decreased susceptibility or resistance are compiled.